Literature DB >> 27930362

Monitoring of procalcitonin but not interleukin-6 is useful for the early prediction of anastomotic leakage after colorectal surgery.

Urszula Zielińska-Borkowska1, Naser Dib1, Wiesław Tarnowski1, Tomasz Skirecki1.   

Abstract

BACKGROUND: Early recognition of patients who have developed anastomotic leakage (AL) after colorectal surgery is crucial for the successful treatment of this complication. The aim of this study was to assess the usefulness of the assessment of procalcitonin (PCT) and interleukin-6 (IL-6) levels in the prognosis of AL.
METHODS: This observational study included 157 patients who underwent major elective colorectal surgery. The most common indications for surgery were cancer and inflammatory bowel diseases. Serum samples were obtained directly before surgery (D0) and 1 day (D1) after surgery, and the relationships between the serum concentrations of PCT and IL-6 and development of AL were assessed.
RESULTS: In total, 10.2% of patients developed post-surgical infections due to AL. PCT levels on D1 were significantly higher in patients who developed AL [2.73 (1.40-4.62)] than in those who recovered without complications [0.2 (0.09-0.44)]. The area under the ROC curve for PCT on D1 was 0.94, 95% CI (0.89-0.98). The sensitivity and specificity of the prediction of an infection were 87% and 87%, respectively, for PCT on D1, which was higher than 1.09 ng/mL. The increase in PCT concentration between D0 and D1 was significantly higher in patients with AL (p<0.001). Patients who developed AL had higher concentrations of IL-6 on D1, but the difference was not significant (p=0.28).
CONCLUSIONS: This study confirms that surgical trauma increases serum PCT concentrations and that the concentration of PCT on D1 can predict AL after colorectal surgery. However, IL-6 is not a good early marker for developing AL.

Entities:  

Keywords:  anastomotic leakage; biomarker; interleukin-6; procalcitonin

Mesh:

Substances:

Year:  2017        PMID: 27930362     DOI: 10.1515/cclm-2016-0736

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

Review 1.  Procalcitonin: Where Are We Now?

Authors:  Bachar Hamade; David T Huang
Journal:  Crit Care Clin       Date:  2019-10-21       Impact factor: 3.598

2.  The Role of Heart Rate, Body Temperature, and Respiratory Rate in Predicting Anastomotic Leakage following Surgery for Rectal Cancer.

Authors:  Jiajun Luo; Hongxue Wu; Yue Jiang; Yu Yang; Jingwen Yuan; Qiang Tong
Journal:  Mediators Inflamm       Date:  2021-08-19       Impact factor: 4.711

3.  Inflammatory response and optimalisation of perioperative fluid administration during hyperthermic intraoperative intraperitoneal chemotherapy surgery.

Authors:  Piet de Witte; Christien A de Witt; Johan L van de Minkelis; Djamila Boerma; H Frank Solinger; C Erik Hack; Peter Bruins
Journal:  J Gastrointest Oncol       Date:  2019-04

Review 4.  Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities.

Authors:  Giuseppe Lippi; Fabian Sanchis-Gomar
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

Review 5.  Risk Factors and Preventive Measures for Anastomotic Leak in Colorectal Cancer.

Authors:  Yongqing Zhao; Bo Li; Yao Sun; Qi Liu; Qian Cao; Tao Li; Jiannan Li
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Predictive and Diagnostic Biomarkers of Anastomotic Leakage: A Precision Medicine Approach for Colorectal Cancer Patients.

Authors:  Mark Gray; Jamie R K Marland; Alan F Murray; David J Argyle; Mark A Potter
Journal:  J Pers Med       Date:  2021-05-25

7.  Use of inflammatory markers in the early detection of infectious complications after laparoscopic colorectal cancer surgery with the ERAS protocol.

Authors:  Mateusz Wierdak; Magdalena Pisarska; Beata Kuśnierz-Cabala; Michał Kisielewski; Piotr Major; Jan S Witowski; Piotr Ceranowicz; Marcin Strzałka; Andrzej Budzyński; Michał Pędziwiatr
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-05-16       Impact factor: 1.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.